Our Principal, Ms. Yolanda Wang, was invited to join a panel discussion on the first day of BIOHK this year, which took place on Wednesday, September 13, 2023 at HKCEC, on the topic of “Ethics in the Biotech Industry.”

The panel was moderated by Ms. Monin Ung of Mung Legal and included esteemed panelists Prof. Yi Rao from Capital Medical University and Prof. Dong Dong from CUHK.

During the discussion, Yolanda shared her experiences regarding the ethical challenges she encountered in her career in IP and provided insights on the concept of ethics in the biotech industry from the perspective of a patent practitioner.



Our Past Events

Recommended Insights

Updates on Hong Kong Patents Examination Guidelines in 2024

29 February 2024
The Intellectual Property Department of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China (HKIPD) has recently made several updates to the Hong Kong Patents Examination Guidelines, effective from 26 January, 2024. These changes mainly clarify and reflect the Registry’s current practices regarding patent examination for Standard Patent (R) […]

Thin Disclosure but "Bulletproof" Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data

8 January 2026
In China, innovative drug companies typically rely on their initial composition of matter patents to block out competitors. Other “follow-on” IP, such as those directed towards formulations, polymorphs, and salt forms, are often regarded as less likely to survive invalidation challenges, especially in China where the standard of “person skilled in the art” is so […]

Introducing the New USPTO Cancer Moonshot Expedited Examination Pilot Program

10 January 2023
Starting from February 1, 2023, the USPTO will begin the new Cancer Moonshot Expedited Examination Pilot Program that advances out-of-turn applications that are directed to oncology or smoking cessation. This new program will replace the Cancer Immunotherapy Pilot Program that has been in place since 2016, and covers more technologies than only cancer immunotherapies. Applications […]

Diagnostic Claims in China

9 January 2020
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]
Top crossarrow-right